Akebia Therapeutics (AKBA) FCF Margin Growth (3y) (2020 - 2026)
Akebia Therapeutics (AKBA) FCF Margin Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 253.00 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1,444.00 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -990.00 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -2,377.00 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -1,484.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4,765.00 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1,067.00 |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | 986.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 986.00 |
| Dec 31, 2025 | 14,788.00 |
| Sep 30, 2025 | -91.00 |
| Jun 30, 2025 | 5,504.00 |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | -4,950.00 |
| Sep 30, 2024 | 10,486.00 |
| Jun 30, 2024 | 9,344.00 |
| Mar 31, 2024 | 7,118.00 |
| Dec 31, 2023 | 13,283.00 |
| Sep 30, 2023 | 18,892.00 |
| Jun 30, 2023 | -2,988.00 |
| Mar 31, 2023 | 5,034.00 |
| Dec 31, 2022 | 18,136.00 |
| Sep 30, 2022 | -3,599.00 |
| Jun 30, 2022 | 11,921.00 |
| Mar 31, 2022 | -2.29 Mn |
| Dec 31, 2021 | 18,185.00 |
| Sep 30, 2021 | -9,929.00 |
| Jun 30, 2021 | -32,345.00 |